PYC Therapeutics (ASX:PYC) Other Stockholders Equity: A$0.00 Mil (As of Dec. 2025)


ASX:PYC PYC Therapeutics Ltd ASX:PYC
36 GF Score
Price A$1.62
! 2 Warning Signs
View Full Analysis

What is PYC Therapeutics Other Stockholders Equity?

PYC Therapeutics ASX:PYC -3.87% 36 Other Stockholders Equity is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:PYC with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

PYC Therapeutics's Other Stockholders Equity for the quarter that ended in Dec. 2025 was A$0.00 Mil.

PYC Therapeutics's quarterly Other Stockholders Equity increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil) but then stayed the same from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$0.00 Mil).

PYC Therapeutics's annual Other Stockholders Equity increased from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$0.00 Mil) and increased from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil).

PYC Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for PYC Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PYC Therapeutics Other Stockholders Equity Chart

PYC Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 0.00

PYC Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:PYC
36GF Score
PYC Therapeutics Ltd ASX:PYC
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PYC Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of A$0.00 Mil mean?
PYC Therapeutics (ASX:PYC) has a Other Stockholders Equity of A$0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on PYC Therapeutics and its competitors.
Is PYC Therapeutics' Other Stockholders Equity too high?
PYC Therapeutics' current Other Stockholders Equity is A$0.00 Mil. Overall, PYC Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' Other Stockholders Equity compare to VRTX and REGN?
PYC Therapeutics' Other Stockholders Equity of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on PYC Therapeutics and its competitors. PYC Therapeutics's current Other Stockholders Equity is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current Other Stockholders Equity of A$0.00 Mil. The current Other Stockholders Equity is A$0.00 Mil. PYC Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current Other Stockholders Equity is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
36GF Score

Get the complete analysis for ASX:PYC

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.62
Price